Pacira BioSciences Inc. (PCRX)
| Bid | 24 |
| Market Cap | 1.16B |
| Revenue (ttm) | 700.97M |
| Net Income (ttm) | -99.56M |
| EPS (ttm) | -2.15 |
| PE Ratio (ttm) | -11.64 |
| Forward PE | 7.82 |
| Analyst | Buy |
| Ask | 28.91 |
| Volume | 763,920 |
| Avg. Volume (20D) | 944,698 |
| Open | 24.93 |
| Previous Close | 24.56 |
| Day's Range | 24.36 - 25.34 |
| 52-Week Range | 11.16 - 31.67 |
| Beta | 0.71 |
About PCRX
Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for healthcare practitioners and their patients in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature only to targeted ner...
Analyst Forecast
According to 9 analyst ratings, the average rating for PCRX stock is "Buy." The 12-month stock price forecast is $25, which is a decrease of -0.08% from the latest price.
Stock ForecastsNext Earnings Release
Analysts project revenue of ... Unlock content with Pro Subscription
1 month ago · seekingalpha.com
Pacira BioSciences: Back On An Uptrend After Positive DevelopmentsPacira BioSciences, Inc.'s stock is up 33% since my last “Buy” rating, driven by strategic moves and market overreaction correction. The company has secured a new patent for its lead pain therapeutic,...
